Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostatic Neoplasms × Biguanides × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Insulin Resistance 2 Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Ketosis 1 Glioma 1 Glioblastoma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Docetaxel 253 Prednisone 215 enzalutamide 155 Leuprolide 155 Radiotherapy 148 Abiraterone Acetate 138 Magnetic Resonance Spectroscopy 135 bicalutamide 118 Goserelin 118 Androgen Antagonists 99 Radiosurgery 94 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 92 apalutamide 72 gallium 68 PSMA-11 65 abiraterone 63 Specimen Handling 63 Gonadotropin-Releasing Hormone 53 Radiation 52 darolutamide 50 cabazitaxel 48 Triptorelin Pamoate 48 Brachytherapy 45 pembrolizumab 44 Zoledronic Acid 43 Estramustine 42 Carboplatin 42 luprolide acetate gel depot 41 Biopsy 41 Flutamide 40 Standard of Care 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02497638 2021-04-19

LIGAND

University Health Network, Toronto

Phase 2 Withdrawn

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡